PharmiWeb.com - Global Pharma News & Resources
30-May-2019

Creative Biolabs Released a Comprehensive Antibody Design and Conjugation Service

As a biopharmaceutical company highly specialized in advanced antibody biochemistry and engineering, Creative Biolabs recently has launched a comprehensive antibody design and conjugation service, intending to become the best companion of global clients in custom ADC field.

 

Antibody drug conjugate (ADC), generally refers to a monocule compound consisting of a desirable monoclonal antibody, an active cytotoxic payload, and a suitable molecular linker, in which the antibody is the key for target specificity and serves as the cargo to deliver the cytotoxic drug (payload). A payload can be attached to different sites on an antibody in the use of diverse conjugation chemistry.

 

“To retain antibody bioactivity, mild, near-physiological conditions are often used for conjugation reactions. Under these conditions, endogenous amino acids such as Lys and Cys are chemically reactive and can be used as conjugation sites. We made a great effort to complete this complicated and difficult task by engineering special moieties with unique drug conjugation chemistries into antibody sequences in our antibody design services.” A scientist from Creative Biolabs said that.

 

“Alongside the efforts of antibody engineering, we also apply several enzymatic or physical approaches to afford site-specific antibody-drug conjugations by modifying the carbohydrate moiety via galactosidases and galactosyltransferases or photo-crosslinking indole-3-butyric acid containing linkers onto antibody nucleotide binding site.”

 

As an international cooperation, Creative Biolabs has established offices all around the globe with more than 200 well-trained full-time scientists and technicians, who work closely with our customers and research partners to develop new medicines for a better, healthier world.

 

 

About Creative Biolabs

 

Established in 2004, Creative Biolabs is highly specialized in advanced antibody biochemistry and engineering. With more than a decade of exploration and expansion, our current research and service capacity covers the entire new drug discovery and development pipeline, ranging from early discovery, preclinical evaluations, cGMP manufacturing, to clinical trials. As an international cooperation, we have established offices all around the globe with more than 200 well-trained full-time scientists and technicians, who work closely with our customers and research partners to develop new medicines for a better, healthier world. 

 

Editor Details

Related Links

Last Updated: 30-May-2019